IL0011839383
IL0011839383
Alpha Tau Medical Ltd.
Loading chart...
Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Latest News

GlobeNewswire • 10/05/2026
Alpha Tau to Participate in October Investor Conferences
MT Newswires • 10/05/2026
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher

GlobeNewswire • 09/02/2026
Alpha Tau to Participate in September Investor Conferences
MT Newswires • 08/31/2026
Alpha Tau Medical Completes Patient Enrollment in Pancreatic Cancer Study
Zacks Small Cap Research • 08/28/2026
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
80.3% p.a.
Max Drawdown (5Y)
-86.9%
Sharpe Ratio (5Y)
0.06
Beta Factor
1.22
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (80.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.9% in the extended horizon.